Last reviewed · How we verify
humanised monoclonal antibody epratuzumab
humanised monoclonal antibody epratuzumab is a Biologic drug developed by Queen Mary University of London. It is currently in Phase 1 development.
At a glance
| Generic name | humanised monoclonal antibody epratuzumab |
|---|---|
| Sponsor | Queen Mary University of London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- humanised monoclonal antibody epratuzumab CI brief — competitive landscape report
- humanised monoclonal antibody epratuzumab updates RSS · CI watch RSS
- Queen Mary University of London portfolio CI
Frequently asked questions about humanised monoclonal antibody epratuzumab
What is humanised monoclonal antibody epratuzumab?
humanised monoclonal antibody epratuzumab is a Biologic drug developed by Queen Mary University of London.
Who makes humanised monoclonal antibody epratuzumab?
humanised monoclonal antibody epratuzumab is developed by Queen Mary University of London (see full Queen Mary University of London pipeline at /company/queen-mary-university-of-london).
What development phase is humanised monoclonal antibody epratuzumab in?
humanised monoclonal antibody epratuzumab is in Phase 1.